instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the outcome of reaction 'Acute hepatic failure'? | Pericarditis Caused by Enterococcus faecium with Acute Liver Failure Treated by a Multifaceted Approach including Antimicrobials and Hemoadsorption.
Sepsis and septic shock are still life-threatening diseases with a high mortality rate. We report a complex case of peritonitis with pericarditis and acute liver failure c... | Recovering | ReactionOutcome | CC BY | 33815848 | 19,242,232 | 2021 |
What was the outcome of reaction 'Drug-induced liver injury'? | Pericarditis Caused by Enterococcus faecium with Acute Liver Failure Treated by a Multifaceted Approach including Antimicrobials and Hemoadsorption.
Sepsis and septic shock are still life-threatening diseases with a high mortality rate. We report a complex case of peritonitis with pericarditis and acute liver failure c... | Recovering | ReactionOutcome | CC BY | 33815848 | 19,242,232 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | AMBROXOL HYDROCHLORIDE, CEFOPERAZONE SODIUM, LINEZOLID, MAGNESIUM ISOGLYCYRRHIZINATE, METHYLPREDNISOLONE, REMDESIVIR, RUXOLITINIB, THYMALFASIN | DrugsGivenReaction | CC BY | 33815852 | 19,163,026 | 2021 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33815852 | 19,163,026 | 2021 |
What was the administration route of drug 'REMDESIVIR'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33815852 | 19,163,026 | 2021 |
What was the administration route of drug 'RUXOLITINIB'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | Oral | DrugAdministrationRoute | CC BY | 33815852 | 19,163,026 | 2021 |
What was the dosage of drug 'AMBROXOL HYDROCHLORIDE'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | 30 mg (milligrams). | DrugDosage | CC BY | 33815852 | 19,163,026 | 2021 |
What was the dosage of drug 'CEFOPERAZONE SODIUM'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | 3 g (grams). | DrugDosage | CC BY | 33815852 | 19,163,026 | 2021 |
What was the dosage of drug 'CEFOPERAZONE SODIUM\SULBACTAM SODIUM'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | 3 g (grams). | DrugDosage | CC BY | 33815852 | 19,207,400 | 2021 |
What was the dosage of drug 'DEXAMETHASONE'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | 10 mg (milligrams). | DrugDosage | CC BY | 33815852 | 19,207,400 | 2021 |
What was the dosage of drug 'LINEZOLID'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | .6 g (grams). | DrugDosage | CC BY | 33815852 | 19,163,026 | 2021 |
What was the dosage of drug 'MAGNESIUM ISOGLYCYRRHIZINATE'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | 100 mg (milligrams). | DrugDosage | CC BY | 33815852 | 19,163,026 | 2021 |
What was the dosage of drug 'MEROPENEM'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | 1 g (grams). | DrugDosage | CC BY | 33815852 | 19,207,400 | 2021 |
What was the dosage of drug 'RUXOLITINIB'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | 5 mg (milligrams). | DrugDosage | CC BY | 33815852 | 19,163,026 | 2021 |
What was the dosage of drug 'THYMALFASIN'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | 1.6 mg (milligrams). | DrugDosage | CC BY | 33815852 | 19,163,026 | 2021 |
What was the dosage of drug 'UMIFENOVIR'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | .2 mg (milligrams). | DrugDosage | CC BY | 33815852 | 19,207,400 | 2021 |
What was the outcome of reaction 'Multiple organ dysfunction syndrome'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | Fatal | ReactionOutcome | CC BY | 33815852 | 19,163,026 | 2021 |
What was the outcome of reaction 'Septic shock'? | A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation.
We report a case of coronavirus disease 2019 (COVID-19) after haploidentical transplantation with acute graft-versus-host disease (aGVHD). COVID-19 and aGVHD were improved under treatment with arbidol, remd... | Fatal | ReactionOutcome | CC BY | 33815852 | 19,163,026 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chest discomfort'. | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | ASCORBIC ACID, ATOVAQUONE, AZATHIOPRINE, DARBEPOETIN ALFA, DESMOPRESSIN, FOLIC ACID, LABETALOL\LABETALOL HYDROCHLORIDE, METHYLPREDNISOLONE, MINERALS\VITAMINS, NIFEDIPINE, ONDANSETRON, PREDNISONE, PROGESTERONE, SODIUM FERRIC GLUCONATE COMPLEX, TACROLIMUS | DrugsGivenReaction | CC BY | 33815854 | 19,161,404 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspnoea'. | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | ASCORBIC ACID, ATOVAQUONE, AZATHIOPRINE, DARBEPOETIN ALFA, DESMOPRESSIN, FOLIC ACID, LABETALOL\LABETALOL HYDROCHLORIDE, METHYLPREDNISOLONE, MINERALS\VITAMINS, NIFEDIPINE, ONDANSETRON, PREDNISONE, PROGESTERONE, SODIUM FERRIC GLUCONATE COMPLEX, TACROLIMUS | DrugsGivenReaction | CC BY | 33815854 | 19,161,404 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemophilus infection'. | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | ASCORBIC ACID, ATOVAQUONE, AZATHIOPRINE, DARBEPOETIN ALFA, DESMOPRESSIN, FOLIC ACID, LABETALOL\LABETALOL HYDROCHLORIDE, METHYLPREDNISOLONE, MINERALS\VITAMINS, NIFEDIPINE, ONDANSETRON, PREDNISONE, PROGESTERONE, SODIUM FERRIC GLUCONATE COMPLEX, TACROLIMUS | DrugsGivenReaction | CC BY | 33815854 | 19,161,404 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lung infiltration'. | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | ASCORBIC ACID, ATOVAQUONE, AZATHIOPRINE, DARBEPOETIN ALFA, FOLIC ACID, LABETALOL\LABETALOL HYDROCHLORIDE, METHYLPREDNISOLONE, NIFEDIPINE, ONDANSETRON, PREDNISONE, PROGESTERONE, SODIUM FERRIC GLUCONATE COMPLEX, TACROLIMUS, VITAMINS | DrugsGivenReaction | CC BY | 33815854 | 19,274,429 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Maternal exposure during pregnancy'. | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | ASCORBIC ACID, ATOVAQUONE, AZATHIOPRINE, DARBEPOETIN ALFA, FOLIC ACID, LABETALOL\LABETALOL HYDROCHLORIDE, METHYLPREDNISOLONE, NIFEDIPINE, ONDANSETRON, PREDNISONE, PROGESTERONE, SODIUM FERRIC GLUCONATE COMPLEX, TACROLIMUS, VITAMINS | DrugsGivenReaction | CC BY | 33815854 | 19,274,429 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Premature delivery'. | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | AZATHIOPRINE, METHYLPREDNISOLONE, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33815854 | 19,322,823 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | ASCORBIC ACID, ATOVAQUONE, AZATHIOPRINE, DARBEPOETIN ALFA, FOLIC ACID, METHYLPREDNISOLONE, ONDANSETRON, PREDNISONE, TACROLIMUS, VITAMINS | DrugsGivenReaction | CC BY | 33815854 | 19,144,899 | 2021 |
What is the weight of the patient? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | 1.1 kg. | Weight | CC BY | 33815854 | 19,326,134 | 2021 |
What was the administration route of drug 'ASCORBIC ACID'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Transplacental | DrugAdministrationRoute | CC BY | 33815854 | 19,269,564 | 2021 |
What was the administration route of drug 'ATOVAQUONE'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Transplacental | DrugAdministrationRoute | CC BY | 33815854 | 19,269,564 | 2021 |
What was the administration route of drug 'DARBEPOETIN ALFA'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Transplacental | DrugAdministrationRoute | CC BY | 33815854 | 19,269,564 | 2021 |
What was the administration route of drug 'DESMOPRESSIN'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Transplacental | DrugAdministrationRoute | CC BY | 33815854 | 19,269,564 | 2021 |
What was the administration route of drug 'FERRIC GLUCONATE TRIHYDRATE'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Transplacental | DrugAdministrationRoute | CC BY | 33815854 | 19,269,564 | 2021 |
What was the administration route of drug 'FOLIC ACID'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Transplacental | DrugAdministrationRoute | CC BY | 33815854 | 19,269,564 | 2021 |
What was the administration route of drug 'LABETALOL\LABETALOL HYDROCHLORIDE'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Transplacental | DrugAdministrationRoute | CC BY | 33815854 | 19,269,564 | 2021 |
What was the administration route of drug 'NIFEDIPINE'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Transplacental | DrugAdministrationRoute | CC BY | 33815854 | 19,269,564 | 2021 |
What was the administration route of drug 'ONDANSETRON'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Transplacental | DrugAdministrationRoute | CC BY | 33815854 | 19,269,564 | 2021 |
What was the administration route of drug 'SODIUM FERRIC GLUCONATE COMPLEX'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33815854 | 19,161,404 | 2021 |
What was the administration route of drug 'TACROLIMUS'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Transplacental | DrugAdministrationRoute | CC BY | 33815854 | 19,326,134 | 2021 |
What was the dosage of drug 'DESMOPRESSIN'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | MATERNAL DOSE: UNK | DrugDosageText | CC BY | 33815854 | 19,269,564 | 2021 |
What was the dosage of drug 'FERRIC GLUCONATE TRIHYDRATE'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | MATERNAL DOSE: UNK | DrugDosageText | CC BY | 33815854 | 19,269,564 | 2021 |
What was the dosage of drug 'LABETALOL\LABETALOL HYDROCHLORIDE'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | MATERNAL DOSE: UNK | DrugDosageText | CC BY | 33815854 | 19,269,564 | 2021 |
What was the dosage of drug 'MINERALS\VITAMINS'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | PRENATAL VITAMINS | DrugDosageText | CC BY | 33815854 | 19,161,404 | 2021 |
What was the dosage of drug 'SODIUM FERRIC GLUCONATE COMPLEX'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | UNK, FOR A TOTAL OF 5 DOSES | DrugDosageText | CC BY | 33815854 | 19,161,404 | 2021 |
What was the dosage of drug 'VITAMINS'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | UNKNOWN | DrugDosageText | CC BY | 33815854 | 19,274,429 | 2021 |
What was the outcome of reaction 'Maternal exposure during pregnancy'? | A Case of De Novo Antiglomerular Basement Membrane Disease Presenting during Pregnancy.
Background. Acute kidney injury (AKI) requiring dialysis during pregnancy is uncommon. We present a case of a young female diagnosed with antiglomerular basement membrane (anti-GBM) disease during pregnancy. Case Presentation. A 23-... | Recovered | ReactionOutcome | CC BY | 33815854 | 19,274,429 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Coma scale abnormal'. | Moyamoya Syndrome Presenting as Refractory Status Epilepticus in a 32-Year-Old Female.
Moyamoya disease (MMD) is a rare cerebrovascular occlusion condition characterized by progressive stenosis in the terminal portion of the internal carotid arteries on both sides. The measured incidence of MMD is 0.086 per 100,000 pe... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816023 | 19,173,992 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Confusional state'. | Moyamoya Syndrome Presenting as Refractory Status Epilepticus in a 32-Year-Old Female.
Moyamoya disease (MMD) is a rare cerebrovascular occlusion condition characterized by progressive stenosis in the terminal portion of the internal carotid arteries on both sides. The measured incidence of MMD is 0.086 per 100,000 pe... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816023 | 19,173,992 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Generalised tonic-clonic seizure'. | Moyamoya Syndrome Presenting as Refractory Status Epilepticus in a 32-Year-Old Female.
Moyamoya disease (MMD) is a rare cerebrovascular occlusion condition characterized by progressive stenosis in the terminal portion of the internal carotid arteries on both sides. The measured incidence of MMD is 0.086 per 100,000 pe... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816023 | 19,173,992 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lethargy'. | Moyamoya Syndrome Presenting as Refractory Status Epilepticus in a 32-Year-Old Female.
Moyamoya disease (MMD) is a rare cerebrovascular occlusion condition characterized by progressive stenosis in the terminal portion of the internal carotid arteries on both sides. The measured incidence of MMD is 0.086 per 100,000 pe... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816023 | 19,173,992 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Moyamoya disease'. | Moyamoya Syndrome Presenting as Refractory Status Epilepticus in a 32-Year-Old Female.
Moyamoya disease (MMD) is a rare cerebrovascular occlusion condition characterized by progressive stenosis in the terminal portion of the internal carotid arteries on both sides. The measured incidence of MMD is 0.086 per 100,000 pe... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816023 | 19,173,992 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oxygen saturation abnormal'. | Moyamoya Syndrome Presenting as Refractory Status Epilepticus in a 32-Year-Old Female.
Moyamoya disease (MMD) is a rare cerebrovascular occlusion condition characterized by progressive stenosis in the terminal portion of the internal carotid arteries on both sides. The measured incidence of MMD is 0.086 per 100,000 pe... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816023 | 19,173,992 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Status epilepticus'. | Moyamoya Syndrome Presenting as Refractory Status Epilepticus in a 32-Year-Old Female.
Moyamoya disease (MMD) is a rare cerebrovascular occlusion condition characterized by progressive stenosis in the terminal portion of the internal carotid arteries on both sides. The measured incidence of MMD is 0.086 per 100,000 pe... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816023 | 19,173,992 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tachypnoea'. | Moyamoya Syndrome Presenting as Refractory Status Epilepticus in a 32-Year-Old Female.
Moyamoya disease (MMD) is a rare cerebrovascular occlusion condition characterized by progressive stenosis in the terminal portion of the internal carotid arteries on both sides. The measured incidence of MMD is 0.086 per 100,000 pe... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816023 | 19,173,992 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Unresponsive to stimuli'. | Moyamoya Syndrome Presenting as Refractory Status Epilepticus in a 32-Year-Old Female.
Moyamoya disease (MMD) is a rare cerebrovascular occlusion condition characterized by progressive stenosis in the terminal portion of the internal carotid arteries on both sides. The measured incidence of MMD is 0.086 per 100,000 pe... | TRAMADOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816023 | 19,173,992 | 2021-03-01 |
What was the administration route of drug 'TRAMADOL HYDROCHLORIDE'? | Moyamoya Syndrome Presenting as Refractory Status Epilepticus in a 32-Year-Old Female.
Moyamoya disease (MMD) is a rare cerebrovascular occlusion condition characterized by progressive stenosis in the terminal portion of the internal carotid arteries on both sides. The measured incidence of MMD is 0.086 per 100,000 pe... | Oral | DrugAdministrationRoute | CC BY | 33816023 | 19,173,992 | 2021-03-01 |
What was the outcome of reaction 'Moyamoya disease'? | Moyamoya Syndrome Presenting as Refractory Status Epilepticus in a 32-Year-Old Female.
Moyamoya disease (MMD) is a rare cerebrovascular occlusion condition characterized by progressive stenosis in the terminal portion of the internal carotid arteries on both sides. The measured incidence of MMD is 0.086 per 100,000 pe... | Fatal | ReactionOutcome | CC BY | 33816023 | 19,173,992 | 2021-03-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | BALSALAZIDE, CYCLOSPORINE, INFLIXIMAB, MERCAPTOPURINE, MESALAMINE, METHOTREXATE, USTEKINUMAB, VEDOLIZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33816098 | 19,144,951 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemangioma'. | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | METHOTREXATE, USTEKINUMAB | DrugsGivenReaction | CC BY-NC-ND | 33816098 | 19,110,452 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mycoplasma infection'. | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | METHOTREXATE, USTEKINUMAB | DrugsGivenReaction | CC BY-NC-ND | 33816098 | 19,110,452 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | METHOTREXATE, USTEKINUMAB | DrugsGivenReaction | CC BY-NC-ND | 33816098 | 19,110,452 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | BALSALAZIDE, CYCLOSPORINE, INFLIXIMAB, MERCAPTOPURINE, MESALAMINE, METHOTREXATE, USTEKINUMAB, VEDOLIZUMAB | DrugsGivenReaction | CC BY-NC-ND | 33816098 | 19,170,574 | 2021-06 |
What was the administration route of drug 'USTEKINUMAB'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | Subcutaneous | DrugAdministrationRoute | CC BY-NC-ND | 33816098 | 19,116,678 | 2021-06 |
What was the dosage of drug 'METHOTREXATE'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | UNKNOWN | DrugDosageText | CC BY-NC-ND | 33816098 | 19,125,082 | 2021-06 |
What was the dosage of drug 'USTEKINUMAB'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | UNKNOWN | DrugDosageText | CC BY-NC-ND | 33816098 | 19,125,082 | 2021-06 |
What was the outcome of reaction 'Acute pulmonary histoplasmosis'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | Recovering | ReactionOutcome | CC BY-NC-ND | 33816098 | 19,111,647 | 2021-06 |
What was the outcome of reaction 'Haemangioma of liver'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | Recovering | ReactionOutcome | CC BY-NC-ND | 33816098 | 19,111,647 | 2021-06 |
What was the outcome of reaction 'Haemangioma'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | Recovering | ReactionOutcome | CC BY-NC-ND | 33816098 | 19,110,452 | 2021-06 |
What was the outcome of reaction 'Hepatic infection fungal'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | Recovering | ReactionOutcome | CC BY-NC-ND | 33816098 | 19,111,647 | 2021-06 |
What was the outcome of reaction 'Hepatosplenomegaly'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | Recovering | ReactionOutcome | CC BY-NC-ND | 33816098 | 19,111,647 | 2021-06 |
What was the outcome of reaction 'Histoplasmosis disseminated'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | Recovering | ReactionOutcome | CC BY-NC-ND | 33816098 | 19,170,574 | 2021-06 |
What was the outcome of reaction 'Histoplasmosis'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | Recovering | ReactionOutcome | CC BY-NC-ND | 33816098 | 19,111,647 | 2021-06 |
What was the outcome of reaction 'Mycoplasma infection'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | Recovered | ReactionOutcome | CC BY-NC-ND | 33816098 | 19,110,452 | 2021-06 |
What was the outcome of reaction 'Mycoplasma test positive'? | Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.
Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated signif... | Recovered | ReactionOutcome | CC BY-NC-ND | 33816098 | 19,111,647 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dermatitis acneiform'. | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | CISPLATIN, ETOPOSIDE, GEFITINIB, GEMCITABINE, PACLITAXEL, PAMIDRONATE DISODIUM, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816221 | 19,217,082 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | CISPLATIN, ETOPOSIDE, GEFITINIB, GEMCITABINE, PACLITAXEL, PAMIDRONATE DISODIUM, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816221 | 19,217,082 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | CISPLATIN, ETOPOSIDE, GEFITINIB, GEMCITABINE, PACLITAXEL, PAMIDRONATE DISODIUM, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816221 | 19,217,082 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neuropathy peripheral'. | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | CISPLATIN, ETOPOSIDE, GEFITINIB, GEMCITABINE, PACLITAXEL, PAMIDRONATE DISODIUM, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816221 | 19,217,082 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Paronychia'. | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | CISPLATIN, ETOPOSIDE, GEFITINIB, GEMCITABINE, PACLITAXEL, PAMIDRONATE DISODIUM, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816221 | 19,217,082 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Small cell carcinoma'. | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | CISPLATIN, ETOPOSIDE, GEFITINIB, GEMCITABINE, PACLITAXEL, PAMIDRONATE DISODIUM, TOPOTECAN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 33816221 | 19,217,082 | 2021 |
What is the weight of the patient? | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | 62 kg. | Weight | CC BY | 33816221 | 19,217,082 | 2021 |
What was the dosage of drug 'ETOPOSIDE'? | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | FOUR CYCLES | DrugDosageText | CC BY | 33816221 | 19,217,082 | 2021 |
What was the dosage of drug 'GEFITINIB'? | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | SECOND LINE THERAPY | DrugDosageText | CC BY | 33816221 | 19,217,082 | 2021 |
What was the dosage of drug 'GEMCITABINE'? | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | 4TH CYCLE | DrugDosageText | CC BY | 33816221 | 19,217,082 | 2021 |
What was the dosage of drug 'PACLITAXEL'? | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | THREE CYCLES OF FULL?DOSE | DrugDosageText | CC BY | 33816221 | 19,217,082 | 2021 |
What was the dosage of drug 'PAMIDRONATE DISODIUM'? | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | UP TO 25 CYCLES OF 4 WEEKLY | DrugDosageText | CC BY | 33816221 | 19,217,082 | 2021 |
What was the dosage of drug 'TOPOTECAN HYDROCHLORIDE'? | Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report.
The acquired resistance mechanisms in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer, particularly adenocarcinoma (ADC), following treatment wi... | 4 MILLIGRAM/SQ. METER, SIX WEEKLY CYCLES | DrugDosageText | CC BY | 33816221 | 19,217,082 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19'. | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | AZITHROMYCIN ANHYDROUS, BENDAMUSTINE HYDROCHLORIDE, BLEOMYCIN SULFATE, BRENTUXIMAB VEDOTIN, CARMUSTINE, CISPLATIN, CYCLOSPORINE, CYTARABINE, DACARBAZINE, DEXAMETHASONE, DOXORUBICIN, EPIRUBICIN, ETOPOSIDE, FAVIPIRAVIR, FLUDARABINE PHOSPHATE, GEMCITABINE, HYDROXYCHLOROQUINE, IFOSFAMIDE, MELPHALAN, METHOTREXATE, MYCOPHENO... | DrugsGivenReaction | CC BY | 33816231 | 19,484,292 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | AZITHROMYCIN ANHYDROUS, BENDAMUSTINE HYDROCHLORIDE, BLEOMYCIN SULFATE, BRENTUXIMAB VEDOTIN, CARMUSTINE, CISPLATIN, CYCLOSPORINE, CYTARABINE, DACARBAZINE, DEXAMETHASONE, DOXORUBICIN, EPIRUBICIN, ETOPOSIDE, FAVIPIRAVIR, FLUDARABINE PHOSPHATE, GEMCITABINE, HYDROXYCHLOROQUINE, IFOSFAMIDE, MELPHALAN, METHOTREXATE, MYCOPHENO... | DrugsGivenReaction | CC BY | 33816231 | 19,484,292 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Epstein-Barr virus associated lymphoproliferative disorder'. | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | BENDAMUSTINE, BRENTUXIMAB VEDOTIN, CISPLATIN, DEXAMETHASONE, GEMCITABINE | DrugsGivenReaction | CC BY | 33816231 | 19,160,636 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Graft versus host disease'. | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | BENDAMUSTINE, BRENTUXIMAB VEDOTIN, CISPLATIN, DEXAMETHASONE, GEMCITABINE | DrugsGivenReaction | CC BY | 33816231 | 19,160,636 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immunodeficiency common variable'. | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | BENDAMUSTINE, BRENTUXIMAB VEDOTIN, CISPLATIN, DEXAMETHASONE, GEMCITABINE | DrugsGivenReaction | CC BY | 33816231 | 19,160,636 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Post transplant lymphoproliferative disorder'. | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | BENDAMUSTINE, BLEOMYCIN SULFATE, BRENTUXIMAB VEDOTIN, CARMUSTINE, CISPLATIN, CYCLOSPORINE, CYTARABINE, DACARBAZINE, DEXAMETHASONE, DOXORUBICIN, EPIRUBICIN, ETOPOSIDE, FLUDARABINE PHOSPHATE, GEMCITABINE, IFOSFAMIDE, MELPHALAN, METHOTREXATE, MYCOPHENOLATE MOFETIL, NIVOLUMAB, RITUXIMAB, VINBLASTINE | DrugsGivenReaction | CC BY | 33816231 | 19,453,188 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | AZITHROMYCIN ANHYDROUS, BENDAMUSTINE HYDROCHLORIDE, BLEOMYCIN SULFATE, BRENTUXIMAB VEDOTIN, CARMUSTINE, CISPLATIN, CYCLOSPORINE, CYTARABINE, DACARBAZINE, DEXAMETHASONE, DOXORUBICIN, EPIRUBICIN, ETOPOSIDE, FAVIPIRAVIR, FLUDARABINE PHOSPHATE, GEMCITABINE, HYDROXYCHLOROQUINE, IFOSFAMIDE, MELPHALAN, METHOTREXATE, MYCOPHENO... | DrugsGivenReaction | CC BY | 33816231 | 19,484,292 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory failure'. | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | AZITHROMYCIN ANHYDROUS, BENDAMUSTINE HYDROCHLORIDE, BLEOMYCIN SULFATE, BRENTUXIMAB VEDOTIN, CARMUSTINE, CISPLATIN, CYCLOSPORINE, CYTARABINE, DACARBAZINE, DEXAMETHASONE, DOXORUBICIN, EPIRUBICIN, ETOPOSIDE, FAVIPIRAVIR, FLUDARABINE PHOSPHATE, GEMCITABINE, HYDROXYCHLOROQUINE, IFOSFAMIDE, MELPHALAN, METHOTREXATE, MYCOPHENO... | DrugsGivenReaction | CC BY | 33816231 | 19,484,292 | 2021 |
What was the administration route of drug 'BENDAMUSTINE HYDROCHLORIDE'? | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33816231 | 19,484,292 | 2021 |
What was the administration route of drug 'HUMAN IMMUNOGLOBULIN G'? | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33816231 | 19,448,979 | 2021 |
What was the dosage of drug 'BENDAMUSTINE HYDROCHLORIDE'? | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | SALVAGE CHEMOTHERAPY | DrugDosageText | CC BY | 33816231 | 19,484,292 | 2021 |
What was the dosage of drug 'BLEOMYCIN SULFATE'? | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | ABVD REGIMEN | DrugDosageText | CC BY | 33816231 | 19,484,292 | 2021 |
What was the dosage of drug 'CARMUSTINE'? | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | BEAM REGIMEN | DrugDosageText | CC BY | 33816231 | 19,484,292 | 2021 |
What was the dosage of drug 'CISPLATIN'? | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | GDP REGIMEN | DrugDosageText | CC BY | 33816231 | 19,484,292 | 2021 |
What was the dosage of drug 'CYTARABINE'? | Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes f... | BEAM REGIMEN | DrugDosageText | CC BY | 33816231 | 19,484,292 | 2021 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.